What does this research mean for the field?

Q: What does this research mean for the field?

Aspirin therapy, including a once-daily 325 mg dose, significantly reduces saphenous vein graft occlusion rates 1 year after coronary artery bypass surgery, particularly in grafts placed to vessels 2.0 mm or less in diameter. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

November 1, 1989CirculationOpen Access

Saphenous vein graft patency 1 year after coronary artery bypass surgery and effects of antiplatelet therapy. Results of a Veterans Administration Cooperative Study.

View Full Paper

Ask AI

Bookmark

Why the study?

Do antiplatelet therapies reduce saphenous vein graft occlusion at 1 year in patients undergoing coronary artery bypass grafting?

Population

406 patients with 1,315 saphenous vein grafts undergoing coronary artery bypass grafting

Comparison

Antiplatelet therapies: 1) aspirin, 2) aspirin… vs Placebo (three times daily)

Design

RCT

Follow-up

1 year

Authors

SGSteven GoldmanHeart Failure & Transplant JCJack G. CopelandHeart Failure / Cardiomyopathy TMThomas MoritzFlorida State University

Discussion

Member takes

Implication

Supports preoperative aspirin initiation and 1-year continuation after CABG; confirms benefit for graft patency.

Structured PICO

Do antiplatelet therapies reduce saphenous vein graft occlusion at 1 year in patients undergoing coronary artery bypass grafting?

Population

406 patients with 1,315 saphenous vein grafts undergoing coronary artery bypass grafting

Intervention

Antiplatelet therapies: 1) aspirin (325 mg once daily), 2) aspirin (325 mg three times daily), 3) aspirin and dipyridamole (325 mg and 75 mg, respectively, three times daily), or 4) sulfinpyrazone (267 mg three times daily). Therapy started preoperatively and continued for 1 year postoperatively.

Comparator

Placebo (three times daily)

Outcome

Graft occlusion rate at 1 year (median 367 days)surrogate

Aspirin therapy started preoperatively and continued for 1 year significantly reduces saphenous vein graft occlusion after coronary artery bypass surgery, particularly in grafts to smaller vessels.

Cite This Study

Goldman et al. (1989) studied this question.

synapsesocial.com/papers/6a125aaeea48cb855a34a7e8 https://doi.org/10.1161/01.cir.80.5.1190

Topics

Dual antiplatelet therapy

View Full Paper

Ask AI

Bookmark

Saphenous vein graft patency 1 year after coronary artery bypass surgery and effects of antiplatelet therapy. Results of a Veterans Administration Cooperative Study.

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Topics

Saphenous vein graft patency 1 year after coronary artery bypass surgery and effects of antiplatelet therapy. Results of a Veterans Administration Cooperative Study.

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider